ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development
- PMID: 15285709
- DOI: 10.1586/14760584.3.4.s99
ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development
Abstract
A decade of clinical trial experience with the preventive use of ALVAC-HIV (Aventis Pasteur) has revealed important information on the safety and immunogenicity of HIV vaccines in general. The ability to induce mucosal immune responses and the feasibility of assessing those responses with a systemically delivered HIV vaccine was recently shown with ALVAC-HIV. A critical advance for the HIV vaccine field was the reported direct relationship between cellular immune responses to ALVAC-HIV vaccine in human leukocyte antigen (HLA) B27 and HLA B57 carriers, alleles linked with a favorable HIV prognosis in the setting of natural infection. Other advances include the use of ALVAC-HIV as a heterologous viral boost to enhance cellular responses to an adenovirus-HIV vaccine. All of these observations have important implications for the future of HIV vaccines and need to be considered in the design of the next generation of products.
Similar articles
-
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.J Virol. 2015 Aug;89(16):8525-39. doi: 10.1128/JVI.01265-15. Epub 2015 Jun 3. J Virol. 2015. PMID: 26041302 Free PMC article.
-
Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines.J Virol. 2001 Sep;75(18):8681-9. doi: 10.1128/jvi.75.18.8681-8689.2001. J Virol. 2001. PMID: 11507213 Free PMC article. Clinical Trial.
-
HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals.J Immunol. 2003 Jul 15;171(2):1094-101. doi: 10.4049/jimmunol.171.2.1094. J Immunol. 2003. PMID: 12847284 Clinical Trial.
-
HIV vaccines in infants and children.Paediatr Drugs. 2005;7(5):267-76. doi: 10.2165/00148581-200507050-00001. Paediatr Drugs. 2005. PMID: 16220994 Review.
-
HIV-1 prophylactic vaccine trials in Thailand.Curr HIV Res. 2005 Jan;3(1):17-30. doi: 10.2174/1570162052772933. Curr HIV Res. 2005. PMID: 15638720 Review.
Cited by
-
CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.Vaccine. 2008 Jul 29;26(32):4062-72. doi: 10.1016/j.vaccine.2008.05.018. Epub 2008 Jun 2. Vaccine. 2008. PMID: 18562053 Free PMC article.
-
HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.Expert Rev Vaccines. 2016 Jun;15(6):709-17. doi: 10.1586/14760584.2016.1147354. Epub 2016 Feb 17. Expert Rev Vaccines. 2016. PMID: 26814372 Free PMC article. Review.
-
Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells.Vaccine. 2008 Sep 15;26(39):5004-13. doi: 10.1016/j.vaccine.2008.07.050. Epub 2008 Aug 6. Vaccine. 2008. PMID: 18691624 Free PMC article.
-
A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.PLoS One. 2011;6(9):e24254. doi: 10.1371/journal.pone.0024254. Epub 2011 Sep 16. PLoS One. 2011. PMID: 21949699 Free PMC article. Clinical Trial.
-
Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions.Front Immunol. 2020 Oct 28;11:590780. doi: 10.3389/fimmu.2020.590780. eCollection 2020. Front Immunol. 2020. PMID: 33193428 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
